Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:UTI) with a Outperform and lowers the price target from $14 to $10.
Validation Data On A Novel Prognostic Test Developed By GRAIL In Stage I Lung Cancer Presented At North America Conference On Lung Cancer
Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional TreatmentGRAIL, LLC, a healthcare company whose mission is to
